---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125444"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:51:34.530197+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tempest reports Q3 net loss $10.6M; gets FDA go-ahead for amezalpat Phase 3 in first-line HCC

## Summary
- Net loss of $10.6M ($0.41/sh) in Q3 2024 vs $6.8M ($0.48) in Q3 2023; cash $22.1M, then raised $19.9M net via ATM.
- FDA issued 'Study May Proceed' letter for pivotal Phase 3 trial of amezalpat + atezolizumab + bevacizumab in first-line HCC.
- Announced agreement with Roche to supply atezolizumab globally for the Phase 3 trial; Tempest retains all rights to amezalpat.
- Positive end-of-Phase 2 FDA meeting: agreement on Phase 3 design, dose, statistical plan with early efficacy analysis.
- Expanded leadership: Troy M. Wagner as VP Quality Assurance and Sheldon Mullins as VP Regulatory Affairs.

## SEC filing metadata
- accession: 0000950170-24-125444
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000095017024125444/0000950170-24-125444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000095017024125444/tpst-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125444
- JSON: https://secwatch.observer/filing/0000950170-24-125444.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125444.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.